Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Iowa
Centre Oscar Lambret
Janssen Research & Development, LLC
University of Washington
The Methodist Hospital Research Institute
University of Florida
University Hospitals Bristol and Weston NHS Foundation Trust
M.D. Anderson Cancer Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Bayer
Aarhus University Hospital
University of Washington
University of Arizona
Janssen Research & Development, LLC
Northwestern University
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
CG Oncology, Inc.
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Daiichi Sankyo
Protara Therapeutics
Roswell Park Cancer Institute
EMD Serono
Massachusetts General Hospital
Swiss Cancer Institute
Boehringer Ingelheim
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Utah
Seagen Inc.
Changhai Hospital
Mayo Clinic
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
CatalYm GmbH
Mayo Clinic
RenJi Hospital
IRCCS San Raffaele
Merck Sharp & Dohme LLC
NRG Oncology